Clinical Scenario:
A 14-year-old boy with Wilson disease was started on D-penicillamine and pyridoxine 12 months ago. He has been fully compliant with treatment and a low-copper diet. However, he continues to have progressive dystonia, dysarthria, and worsening tremor. Liver function tests have improved, but his neurological symptoms have continued to deteriorate. There is no evidence of hepatic decompensation.
What is the most appropriate next step in management?
A. Double the dose of D-penicillamine
B. Add oral zinc while continuing D-penicillamine
C. Switch D-penicillamine to trientine
D. Stop chelation therapy and continue dietary copper restriction alone
E. Proceed directly to liver transplantation
Correct Answer & Explanation:
Correct answer: C. Switch D-penicillamine to trientine
Explanation: Wilson Disease / Neurological Worsening
This adolescent has Wilson disease with progressive neurological worsening despite good adherence to D-penicillamine. The deterioration includes worsening dystonia, dysarthria, and tremor, while his liver function has improved and there is no hepatic decompensation.
Neurological worsening can occur after initiation of D-penicillamine, particularly in patients who present with neurological manifestations. The mechanism is thought to involve an initial increase in circulating free copper during chelation, which may aggravate neurological injury.
In a pediatric series, neurological worsening occurred in approximately 22% of children and adolescents receiving D-penicillamine. Patients who developed neurological deterioration were subsequently managed with trientine, zinc, or combinations of these therapies, with improvement reported in most patients.
Therefore, in a child with persistent neurological deterioration attributable to D-penicillamine, switching to another copper chelator such as trientine is an appropriate management strategy.
Why the other options are incorrect
A. Double the dose of D-penicillamine
Increasing D-penicillamine is inappropriate when neurological symptoms are progressively worsening after its initiation. Further exposure may aggravate treatment-associated neurological deterioration.
B. Add oral zinc while continuing D-penicillamine
Zinc is an established treatment for Wilson disease and may be used as maintenance therapy or in selected treatment regimens. However, simply adding zinc while continuing the suspected offending chelator does not address the neurological deterioration attributed to D-penicillamine.
D. Stop chelation therapy and continue dietary copper restriction alone
Wilson disease requires lifelong pharmacological therapy to remove excess copper or reduce intestinal copper absorption. Dietary copper restriction alone is inadequate for established symptomatic disease.
E. Proceed directly to liver transplantation
Liver transplantation has an established role in Wilson disease with acute liver failure or selected severe hepatic disease, but this child has no hepatic decompensation. Progressive neurological symptoms alone do not automatically mandate transplantation.
High-yield exam pearl
Neurological deterioration can paradoxically worsen after initiation of chelation therapy in Wilson disease. When significant neurological worsening occurs with D-penicillamine, switching to trientine is an important management option, particularly in children and adolescents. Treatment should not be stopped altogether because Wilson disease requires lifelong control of copper accumulation.
You can also practice another MCQ on Management of Acute Liver Failure
References
- Schilsky ML, Roberts EA, Bronstein JM, Dhawan A, Hamilton JP, Rivard AM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2022;76(5):1428-1455.
- Wilson disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(2):334-344.
- Management of children and adolescents with Wilson disease and neurological worsening following D-penicillamine therapy: a single centre experience. Ann Indian Acad Neurol. 2022.
